Cargando…
"Resurrection of clinical efficacy" after resistance to endocrine therapy in metastatic breast cancer
BACKGROUND: In a significant proportion of metastatic breast cancer (MBC) patients whose tumour has progressed within 6 months of endocrine therapy (de novo resistance), it is generally believed that the chance of achieving clinical benefit (CB) with further endocrine therapy is minimal. METHODS: Da...
| Autores principales: | , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2006
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1538598/ https://www.ncbi.nlm.nih.gov/pubmed/16822312 http://dx.doi.org/10.1186/1477-7819-4-40 |